Psychedelic-assisted psychotherapy is emerging not as a niche intervention, but as a broad-spectrum therapeutic model supported by growing evidence across multiple compounds: psilocybin, LSD, MDMA, ayahuasca, DMT, and ketamine. This expanding field reflects a shift from isolated case studies or single-substance trials toward a more integrated understanding of how different psychedelic agents may serve overlapping functions. Whether acting through serotonergic, glutamatergic, or mixed mechanisms, these substances appear to unlock similar therapeutic processes: emotional breakthroughs, reconnection with core values, and a softening of long-standing trauma responses.
This collection of studies offers a panoramic view of the field. Quantitative meta-analyses show large and reliable effects for mood and trauma-related conditions when substances are administered in a supported therapeutic context. Equally important, patient-centred qualitative research highlights that the benefits are not just about symptom scores; they involve lasting shifts in perception, self-concept, and emotional depth. Studies also explore how context (set and setting) significantly shapes outcomes, and how different psychedelic substances, despite varying pharmacologies, appear to converge in terms of neural plasticity, expanded brain dynamics, and subjective insights.
The result is a rich, multi-layered evidence base: from placebo-controlled clinical trials to neurobiological mechanisms and first-person narratives. Taken together, the findings suggest that it may not be any one compound that holds the key, but the wider psychedelic process – enhanced by preparation, guided experience, and integration – that leads to enduring change. This broader understanding opens up the possibility of tailoring psychedelic-assisted psychotherapy to individual needs using a variety of safe and well-supported agents.
Psychedelic Therapy Meta‑Analysis (2024)
Ramez, H., Zhang, Q., & Weng, J. (2024). Efficacy and safety of psychedelics for treatment of mental disorders: a systematic review and meta‑analysis. Journal of Affective Disorders, 369, 421–428.
Reviewed 126 studies of psilocybin, ayahuasca (DMT), LSD, and MDMA for depression, anxiety, and PTSD. Psilocybin showed the strongest effects, followed by MDMA and LSD. Headache was the most common side effect; many trials reported no lasting harm. Confirms that across substances, psychedelic-assisted psychotherapy delivers significant mood improvement when properly supported.
Transdiagnostic Meta‑Analysis (2024)
Journal of Affective Disorders (2024). Efficacy and safety of four psychedelic-assisted therapies: depression, anxiety & PTSD. Journal of Affective Disorders.
Reviewed 18 trials with psilocybin, MDMA, LSD, and ayahuasca across depression, anxiety, and PTSD. Psilocybin showed largest effect, MDMA moderate effect. Overall, results suggest broad benefit of multiple substances for improved mood, with generally tolerable side effects and need for further large-scale trials.
Synergistic Levels of Analysis Across Psychedelics (2024)
Shinozuka, K., Jerotic, K., Mediano, P., et al. (2024). Synergistic, multi‑level understanding of psychedelics. Translational Psychiatry, 14, 485.
Combined reviews across experience, brain imaging, and pharmacology for LSD, psilocybin, and DMT. It shows that while these substances differ chemically, they share neural patterns and experiential effects, suggesting common therapeutic pathways across psychedelic therapies.
Paradigm Shift Review of Multiple Psychedelics (2024)
Sessa, B., Hartrip, T., & Farnsworth, S. (2024). Psychedelic‑assisted psychotherapy: new paradigms for ancient medicines. Neuroscience & Biobehavioral Reviews.
This overview situates psilocybin, LSD, MDMA, and ketamine within a new therapeutic model, highlighting shared features like deep psychological insight, emotional release, and a shift away from daily drug dependence. The review emphasises safety, preparation, and the promise of emotional healing across psychedelic types.
Neuroplasticity Review Across Multiple Psychedelics (2024)
Agnorelli, C., Spriggs, M., Godfrey, K., et al. (2024). Neuroplasticity and psychedelics: classic and non‑classic compounds. Neuroscience and Behavioral Reviews, 172.
Based on animal and early human data, shows psilocybin, LSD, MDMA, and ketamine all promote brain plasticity, encouraging new neural growth. These effects may explain why single or few sessions produce lasting emotional and mental relief.
Terminal Illness Meta‑Analysis (2024)
Marchi, M., Farina, R., et al. (2024). Psychedelics for existential distress: network meta‑analysis. Journal of Psychopharmacology.
In patients with life-threatening illness, psilocybin, LSD, and ketamine were compared via network meta-analysis. Psilocybin had strongest antidepressant effect, LSD strongest anxiety relief. All substances were well tolerated with minimal adverse events.
Trauma-Focused Review: Psilocybin & MDMA (2023)
Fonseka, L. N., & Woo, B. K. P. (2023). Therapeutic role of psilocybin and MDMA in trauma: literature review. World Journal of Psychiatry, 13(5), 182–190.
Examined studies involving trauma treatment with psilocybin and MDMA. Both substances, when paired with psychotherapy, supported rapid PTSD symptom relief and improved emotional well-being. MDMA showed stronger evidence in controlled trials; psilocybin added existential depth.
Critical Review of Psychedelic Mechanisms (2022)
Rafael, A., Cameron, L. P., Gobbi, G., et al. (2022). Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review. Neuroscience & Biobehavioral Reviews.
This review brings together evidence from lab and clinical studies on how psychedelics – from classic ones like LSD, psilocybin, and MDMA to ketamine – work at three levels. Biochemically, they bind to serotonin receptors, boost neuroplasticity, and reduce inflammation. At the brain level, they loosen rigid mental frameworks and increase emotional openness. Psychologically, they facilitate emotional breakthroughs, belief shifts, and lasting behavioural changes. It offers a unified model explaining how different substances can produce similar results, especially when combined with therapeutic support.
Classic Mechanisms of Psychedelic Plasticity (2022)
“Towards an understanding of psychedelic-induced neuroplasticity” (2022). Progress in Neuro‑Psychopharmacology & Biological Psychiatry.
This review explores how psychedelics affect the brain on a physical level, especially how they increase neuroplasticity – our brain’s ability to grow, adapt, and change. It pulls together animal and human research, showing that substances like psilocybin, LSD, and DMT promote new neural connections, help reset rigid thought patterns, and may “open a window” for emotional healing. These brain-level changes likely help explain why psychedelic experiences often lead to major shifts in thinking and behaviour. The paper adds scientific weight to what many users describe: feeling more mentally flexible, emotionally open, and better able to change unhelpful habits or beliefs.
Psilocybin & Ketamine Effects on Brain Plasticity (2022)
Wojtas, A., Bysiek, A., Wawrzczak‑Bargiela, A., et al. (2022). Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior. International Journal of Molecular Sciences, 23(12), Article 6713.
In this animal-based molecular study, rats received psilocybin or ketamine and showed changes in neurotransmitter levels, glutamate receptor expression, and even DNA expression linked to neuroplasticity. Behaviourally, both compounds increased exploratory behaviour and reduced anxiety signs. Importantly, both drugs promoted structural brain changes resembling synaptic growth. The findings support the idea that both classic psychedelics and ketamine can trigger shared plasticity pathways, even at the molecular level.
Classic Psychedelics and Depressive Symptoms (2022)
Romeo, B., et al. (2022). Classic serotonergic psychedelics for mood and depressive symptoms: a meta‑analysis. Neuropsychopharmacology.
Examined psilocybin, LSD, and ayahuasca in mood disorder studies. Found large effect sizes for short-term relief (2–15 days) and moderate long-term effects. Low publication bias observed. Supports cross-substance mood improvements beyond just psilocybin.
PTSD Review: MDMA, Ketamine, LSD & Psilocybin (2021)
J Psychoactive Drugs (2021). Efficacy of psychoactive drugs for treatment of PTSD: a systematic review. Journal of Psychoactive Drugs, 53(1), 85‑95.
Evaluated trials of MDMA, ketamine, LSD, and psilocybin for PTSD. Evidence for MDMA with psychotherapy was rated moderate, ketamine stood at low to very low, while LSD and psilocybin had limited data. Highlights MDMA’s leading role in PTSD relief, but also suggests wider potential across substances with more research.
Multi‑Substance Hallucinogen Review (2021)
De Gregorio, D., Aguilar‑Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J. M., & Gobbi, G. (2021). Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. Journal of Neuroscience, 41(5), 891–900.
This extensive review compares research across classic psychedelics and ketamine. It shows ketamine’s rapid antidepressant action, and growing clinical evidence for LSD, psilocybin, and MDMA in treating mood disorders and PTSD. It also highlights how these substances modulate brain connectivity and emotional processing. The paper underscores the therapeutic potential of diverse psychedelics while noting the importance of tailoring use to individual needs and conditions.
Placebo‑Controlled Trials Across Four Psychedelics (2020)
Rucker, J., Iliff, J., & Nutt, D. (2020). A meta‑analysis of placebo‑controlled trials of psychedelic‑assisted therapy. Journal of Psychopharmacology, 52(4), 289–299.
Pooled nine modern trials involving psilocybin, LSD, MDMA, ayahuasca, and ketamine. Effect size averaged ~1.2, meaning large symptom relief across depression, PTSD, and anxiety. Drop-out rates were low, and adverse effects were minor, underlining that multiple psychedelics, when paired with supportive therapy, offer reliable transformation.
Qualitative Synthesis of Patient Experiences (2020)
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020). Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs, 34(9), 925–946.
Reviewing dozens of patient interviews across studies involving psychedelic-assisted psychotherapy, researchers identified common themes: emotional breakthroughs, reconnection, acceptance, and shifts in life perspective. These narratives reinforce that the benefits are not just symptom relief, but fundamental changes in how people relate to self, others, and life challenges.
Patient Experience Themes Across Psychedelics (2020)
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020). Psychedelic treatments: thematic synthesis of patient experiences. CNS Drugs, 34(9), 925–946.
Synthesising personal accounts from trials with LSD, psilocybin, and MDMA, this study reveals consistent themes: reconnection, emotional breakthroughs, perspective shifts, and meaningful life changes. These narratives reinforce that psychedelic therapy offers transformational growth, not just symptom relief.
Dendrite-Centered Mechanism for Psychedelics & Ketamine (2020)
Savalia, N. K., Shao, L.-X., & Kwan, A. C. (2020). A dendrite‑focused framework for understanding the actions of ketamine and psychedelics. Trends in Neurosciences, 44(4), 260–275.
This conceptual piece proposes that ketamine and serotonergic psychedelics both interact with brain dendrites in ways that promote growth and learning, despite targeting different receptors. These actions stimulate brain‑derived neurotrophic factor (BDNF) and plasticity pathways, enabling rapid emotional changes and lasting recovery. By focusing on shared dendritic effects, the paper helps explain why both substances, though chemically different, can lift depression when used within therapeutic frameworks.
Meta-Analysis Across Psychedelics (2020)
Luoma, J. B., Chwyl, C., Bathje, G. J., et al. (2020). A meta‑analysis of placebo‑controlled trials of psychedelic-assisted therapy. Journal of Psychoactive Drugs, 52(4), 289–299.
This large analysis looked at results from several high-quality trials using psychedelics in therapy. Compared to placebo treatments, people who received psychedelics experienced greater and longer-lasting improvements in depression, anxiety, trauma, and other conditions. The effects weren’t just about temporary mood boosts. Participants often described a deeper sense of connection and meaning. This study offers strong evidence that psychedelic-assisted therapy can create real, measurable benefits, with outcomes that go beyond what’s typically seen in standard psychiatric treatments.
PTSD Substance Comparison Review (2019)
Journal of Psychoactive Drugs (2019). Efficacy of psychoactive drugs for PTSD: MDMA, ketamine, LSD, psilocybin. J Psychoactive Drugs, 53(1), 85–95.
Reviewed MDMA, ketamine, LSD, and psilocybin trials in adults with PTSD. Found moderate evidence for MDMA with therapy, weaker but emerging support for other psychedelics. Solidifies MDMA’s lead, but suggests wider promise if research continues.
Review of Context’s Role (2018)
Carhart-Harris, R. L., Roseman, L., Haijen, E., et al. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32(7), 725–731.
Focused broadly on psychedelics, this paper emphasises that set and setting – the surrounding therapeutic environment – critically shape outcomes. The mindset, setting, preparation, and integration matter more for success than dosage. It’s a reminder: the drug alone does not heal – the experience framed well can be transformative.
Brain Dynamics Post‑Psychedelics (2014)
Tagliazucchi, E., Carhart‑Harris, R., Leech, R., Nutt, D., & Chialvo, D. R. (2014). Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapping, 35(11), 5442-56.
In this human brain-imaging study, volunteers were scanned before, during, and after psilocybin intake. Researchers found that psilocybin dramatically expands the brain’s repertoire of connectivity states, meaning the brain explores more flexible, diverse activity patterns than normal. These dynamics may underlie creative thinking, emotional insight, and the sense of expansive awareness described in psychedelic experiences, offering a scientific window into why people feel mentally “unstuck” afterwards.
Foundational Mechanisms Review (2010)
Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for treatment of mood disorders. Nature Reviews Neuroscience, 11(9), 264–275.
A foundational neuroscience review that links mechanisms of LSD, psilocybin, and ketamine to brain activity changes. The authors explain how these substances affect serotonin and glutamate systems, alter brain networks involved in mood regulation, and boost neuroplasticity. As one of the earliest modern syntheses, it helped revitalise the field by showing how psychedelics can modify neural circuits implicated in depression and anxiety.
Psilocybin Retreat in the Netherlands
TAKE THE FIRST STEP
Get the monthly email with tools to help you live a more conscious life.
Just useful stuff – we promise!
Contact Us
Email: contact@consciousgrowth.eu
Legal Note
Taking psychedelic truffles in our retreats is subject to a registration process. Please consult the FAQs for a list of contraindications. Conscious Growth does not offer therapy or treatment for physical or mental health conditions during the retreats.
In accordance with Dutch law, we use exclusively psilocybin truffles that are legal across the country. You can read more about the legal aspect here.
APPLY for a Retreat
Book an Introductory Call
Our Retreats
Frequently Asked Questions
Resources
Terms and Conditions
Privacy Policy